Spatial Proteomics Growth Ionpath operates in high-definition spatial proteomics with their MIBIscope platform and recently launched MIBIscope 3.0, signaling expansion opportunities for labs and institutions adoption, service, and integration of advanced imaging workflows.

Strategic Partnerships Active financing and investor support from Bruker and Samsara BioCapital, plus leadership hires in commercial and CEO roles, indicate a strengthened go-to-market approach and potential channel or collaboration opportunities with mass spectrometry and proteomics ecosystems.

Global Support Footprint Post acquisition of MIBIscope IP in 2025 and ongoing global system support, there is a pathway to upsell service contracts, training, and digital resources to existing MIBIscope customers and international research centers.

SMB to Mid-Market Potential Revenue range and employee size place Ionpath between small biotech firms and larger diagnostics players, suggesting prioritization of mid-size research labs and university core facilities as early adoption targets for new platform releases.

Digital & Customer Enablement A tech stack spanning Salesforce, NetSuite, Shopify, and Squarespace indicates a modernized CRM, ERP, e-commerce, and customer experience, offering opportunities to tailor demos, trials, and online resources to accelerate procurement and deployment.